Surmodics Stock News

SurModics (SRDX) delivered earnings and revenue surprises of 63.89% and 3.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Surmodics, Inc. (SRDX) CEO Gary Maharaj on Q1 2022 Results - Earnings Call Transcript

Surmodics press release (SRDX): FQ1 Non-GAAP EPS of -$0.13.Revenue of $23M (+3.1% Y/Y).Surmodics expects fiscal year 2022 revenue to range from $97 million to $101 million vs

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics to Present at Sidoti & Company Virtual Investor Conference on January 19, 2022.

New York State Teachers Retirement System reduced its position in Surmodics, Inc. (NASDAQ:SRDX) by 1.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,326 shares of the companys stock after selling 500 shares during the quarter. New York []

Shares of Surmodics, Inc. (NASDAQ:SRDX) gapped up before the market opened on Tuesday . The stock had previously closed at $44.84, but opened at $47.67. Surmodics shares last traded at $45.99, with a volume of 2 shares. Separately, Needham & Company LLC dropped their price objective on Surmodics from $76.00 to $70.00 and set a []

Assenagon Asset Management S.A. lowered its stake in Surmodics, Inc. (NASDAQ:SRDX) by 2.1% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 103,586 shares of the companys stock after selling 2,230 shares during the period. Assenagon Asset Management S.A. owned approximately 0.75% of Surmodics worth []

Surmodics, Inc. (NASDAQ:SRDX) Director David Dantzker sold 3,475 shares of Surmodics stock in a transaction on Wednesday, November 24th. The stock was sold at an average price of $47.01, for a total transaction of $163,359.75. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Shares of SRDX []

Surmodics (NASDAQ:SRDX) issued an update on its FY 2022 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $-1.750-$-1.250 for the period, compared to the Thomson Reuters consensus estimate of $0.920. The company issued revenue guidance of $97 million-$101 million, compared to the consensus revenue estimate of $118.12 million. Shares []

Surmodics (NASDAQ:SRDX) updated its FY 2022 earnings guidance on Wednesday. The company provided earnings per share guidance of $-1.750-$-1.250 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.920. The company issued revenue guidance of $97 million-$101 million, compared to the consensus revenue estimate of $118.12 million. Separately, Needham & []

Related Stocks: SRDX ,

Millennium Management LLC boosted its position in Surmodics, Inc. (NASDAQ:SRDX) by 113.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 107,421 shares of the companys stock after buying an additional 56,977 shares during the period. Millennium Management LLC owned approximately 0.77% []

Surmodics (NASDAQ:SRDX) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends. Analyst Ratings This is a breakdown of recent ratings and recommmendations for Surmodics and Inovio Pharmaceuticals, []

Surmodics (NASDAQ:SRDX) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership. Profitability This table compares Surmodics and LENSARs net margins, return on equity and return on assets. Net []